Company intelligence / Profile preview

GARDP

Geneva, Switzerland

Ownership: Private
Employees: ~100
Development stage: Other

Overview

GARDP is developing and facilitating access to new antibiotic treatments for drug-resistant infections, with clinical programs and partnerships across multiple continents. It aims to develop five new treatments by 2025, focusing on serious bacterial infections, neonatal sepsis, and STIs. Landmark licensing with Shionogi on cefiderocol is enabling unprecedented access in low- and middle-income countries.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Partnerships

World Health Organization (WHO)Drugs for Neglected Diseases initiative (DNDi)ShionogiClinton Health Access Initiative (CHAI)

Beyond the preview

Go deeper on GARDP.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GARDP.

Explore the full profile